Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 255 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: photodynamic therapy Clear all
Completed Phase 1Phase 2 Interventional

Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia

NCT00077012
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
QLT0074, Photodynamic therapy
Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • New Port Richey, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Oct 12, 2026, 4:37 PM EDT
Withdrawn Phase 2 Interventional

Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity

NCT02119728
View directory record Official record
Conditions
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Oral Cavity
Interventions
HPPH, Light Infusion Therapy™, therapeutic conventional surgery
Drug · Device · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 12, 2026, 4:37 PM EDT
Withdrawn Phase 4 Interventional

Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

NCT04075136
View directory record Official record
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 12, 2026, 4:37 PM EDT
Terminated Phase 2 Interventional

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

NCT00865878
View directory record Official record
Conditions
Actinic Keratoses, Skin Neoplasms
Interventions
Aminolevulinic Acid, Vehicle
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Irvine, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2011 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer

NCT00017485
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Not applicable Interventional

Photodynamic Therapy (PDT) in Lung Cancer

NCT00984243
View directory record Official record
Conditions
Lung Cancer
Interventions
PHOTODYNAMIC THERAPY (PDT)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Oct 12, 2026, 4:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

NCT06307548
View directory record Official record
Conditions
Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer
Interventions
Aminolevulinic Acid, Biospecimen Collection, Computed Tomography, Fluorescence-Guided Surgery, Magnetic Resonance Imaging, Photodynamic Therapy, Surgical Procedure
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 12, 2026, 4:37 PM EDT
Terminated Phase 2 Interventional

Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

NCT00116571
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
Drug · Device
Lead sponsor
QLT Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
San Bernardino, California • Shreveport, Louisiana • Greenbelt, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2006 · Synced Oct 12, 2026, 4:37 PM EDT
Completed No phase listed Observational

Photodynamic Therapy for PDA in NV AMD

NCT02452840
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Macular Degeneration
Interventions
No Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 12, 2026, 4:37 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

NCT00423189
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab (Lucentis), 0.5mg ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
55 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study of Treatment of Pathological Fractures in Humerus

NCT02338492
View directory record Official record
Conditions
Humerus Fracture Metastatic Bone Disease
Interventions
Photodynamic Bone Stabilization System
Device
Lead sponsor
IlluminOss Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Redwood City, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

NCT01469156
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab 0.5 or 2.0 mg/0.05 cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Phase 2 Interventional

Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration

NCT00390208
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab, dexamethasone and verteporfin, Ranibizumab
Drug
Lead sponsor
Bay Area Retina Associates
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Phase 1 Interventional

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

NCT03467789
View directory record Official record
Conditions
Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Interventions
Dietary Vitamin D3 pre-treatment, Photodynamic therapy, Serum Maintenance Vitamin D3
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Phase 3 Interventional

A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration

NCT00061594
View directory record Official record
Conditions
Macular Degeneration
Interventions
rhuFab V2 (ranibizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
70
States / cities
Tucson, Arizona • Beverly Hills, California • Irvine, California + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Use of Microneedles in Photodynamic Therapy

NCT01812837
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Microneedle, Aminolevulinic Acid, Blue light
Device · Drug · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy in Treating Patients With Skin Cancer

NCT00002975
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous Condition
Interventions
aminolevulinic acid
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Oct 12, 2026, 4:37 PM EDT
Completed No phase listed Observational

Twelve Month Follow-Up of CP0108

NCT02209012
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aminolevulinic Acid (ALA), Topical Solution Vehicle, BLU-U Blue Light Photodynamic Therapy Illuminator
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Phase 1 Interventional

Optimizing Photodynamic Therapy of Cutaneous Neoplastic Diseases Via Structured Illumination and Real-time Dosimetry.

NCT00784108
View directory record Official record
Conditions
Skin Cancer, Signs and Symptoms
Interventions
Modulated Imaging (MI), Photodynamic therapy
Device · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Phase 2 Interventional

Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases

NCT00083785
View directory record Official record
Conditions
Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
Interventions
Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED), Photodynamic therapy, Phototherapy, Chemotherapy
Drug · Device · Procedure
Lead sponsor
Light Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 11, 2007 · Synced Oct 12, 2026, 4:37 PM EDT
Terminated Phase 1 Interventional

Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer

NCT00265603
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Extracorporeal Photochemotherapy With Transimmunization
Procedure
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Results available

Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma

NCT01800838
View directory record Official record
Conditions
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome
Interventions
silicon phthalocyanine 4, photodynamic therapy, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Kevin Cooper MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Photodynamic Therapy Incubation Times for Actinic Keratosis

NCT03066843
View directory record Official record
Conditions
Actinic Keratoses
Interventions
ALA (5-aminolevulinic acid), Blue light therapy
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 12, 2026, 4:37 PM EDT
Completed Phase 2 Interventional

Nasal Photodisinfection in All Patients Presenting for Surgery for a Wide Range of Surgical Procedures

NCT05090657
View directory record Official record
Conditions
Surgical Site Infections, Nosocomial Infection, Healthcare Associated Infections
Interventions
methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation
Combination Product
Lead sponsor
Ondine Biomedical Inc.
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 12, 2026, 4:37 PM EDT